← 返回前沿论文

mRNA 疫苗在肿瘤免疫治疗中的最新进展、临床转化与未来展望

英文原题:mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.

查看英文原题

mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.

PubMed 2025/09/15(内容时间) Curr Med Sci Q3 · IF 2(JCR 2025)

研究概要

癌症仍是全球主要的健康负担。

中文摘要

癌症仍是全球主要健康负担。mRNA癌症疫苗凭借快速开发、生产灵活及在传染病领域已证实的疗效,已成为癌症免疫治疗中的变革性方法。尽管相较传统方法具有显著优势,mRNA不稳定及体内递送效率低等挑战仍然存在。不过,技术进步,尤其是脂质纳米颗粒(LNP)等纳米颗粒制剂,已显著缓解这些问题。本综述全面考察mRNA疫苗作用机制,重点关注其编码肿瘤特异性抗原(TSA),尤其新抗原,以及肿瘤相关抗原(TAA),从而诱导强效抗肿瘤免疫应答的能力。我们批判性分析mRNA疫苗作为单药,以及更重要的与免疫检查点抑制剂、化疗、过继细胞疗法(如CAR-T)和放射治疗联合使用,以克服免疫抑制性肿瘤微环境的前景。本综述核心部分综合了黑色素瘤、非小细胞肺癌和前列腺癌等多种癌症关键临床试验的有力结果,突出新抗原特异性T细胞应答诱导、无复发生存期改善及肿瘤客观消退等重要结局。我们还讨论个体化新抗原mRNA疫苗的突破性潜力。我们全面评估当前挑战,包括肿瘤异质性、最佳递送策略、生物标志物鉴定,以及提高治疗效果和安全性,并探讨可能解决方案。最后,我们展望未来方向,重点关注先进纳米疫苗和改进的个体化平台等下一代方法。本综述旨在及时且批判性地分析快速演进的mRNA癌症疫苗领域,凸显其革新癌症治疗模式的巨大潜力。

展开英文摘要原文

Cancer remains a leading global health burden. mRNA cancer vaccines, which are propelled by their rapid development, manufacturing flexibility, and proven efficacy against infectious diseases, have emerged as a transformative approach in cancer immunotherapy. While offering significant advantages over traditional methods, challenges related to mRNA instability and in vivo delivery efficiency persist. However, technological advancements, particularly in nanoparticle formulations such as lipid nanoparticles (LNPs), have substantially mitigated these concerns. This review comprehensively examines the mechanism of action of mRNA vaccines, focusing on their ability to encode tumor-specific antigens (TSAs), particularly neoantigens, and tumor-associated antigens (TAAs) to elicit potent anti-tumor immune responses. We critically analyzed the promising application of mRNA vaccines as monotherapies and, more significantly, in combination with immune checkpoint inhibitors, chemotherapy, adoptive cell therapies (e.g., CAR-T), and radiation to overcome the immunosuppressive tumor microenvironment. The core of this review synthesizes compelling results from key clinical trials across various cancers (e.g., melanoma, non-small cell lung cancer, and prostate cancer), highlighting significant outcomes such as induced neoantigen-specific T-cell responses, improved recurrence-free survival, and objective tumor regression. We also discuss the groundbreaking potential of personalized neoantigen mRNA vaccines. Current challenges, including tumor heterogeneity, optimal delivery strategies, biomarker identification, and enhancing therapeutic efficacy/safety profiles, are thoroughly evaluated alongside potential solutions. Finally, we explore future directions emphasizing next-generation approaches such as advanced nanovaccines and refined personalized platforms. This review aims to provide a timely and critical analysis of the rapidly evolving landscape of mRNA cancer vaccines, underscoring their immense potential to revolutionize cancer treatment paradigms.

论文信息

作者
Pati SS、Dhal S、Pattnaik R、Tripathy S、Kumar S
第一作者单位
School of Biotechnology, KIIT Deemed-to-be-University, Bhubaneswar, 751024, India.India
通讯作者单位
School of Biotechnology, KIIT Deemed-to-be-University, Bhubaneswar, 751024, India. Subrat_kumar@yahoo.com.India
文献类型
综述
期刊
Current medical science2025 Oct
原文标识
PubMed 40952557 · DOI 10.1007/s11596-025-00112-5